Anemia Drugs Market Size & Insights

According to MarkNtel Advisors study The future of Anemia Drugs Market size was valued at around USD 14.62 billion in 2024 and is projected to reach USD 21.73 billion by 2030. Along with this, the market is estimated to grow at a CAGR of around 6.83% during the forecast period, i.e., 2025-30. 

What are the Key Driver in the Anemia Drugs Market?

Innovations in Drug Technologies – There have been several innovations in the Global Anemia Drugs Market with the introduction of oral HIF-prolyl hydroxylase inhibitors, such as daprodustat and roxadustat, as alternatives to injectables, offering convenience and accessibility to patients. These oral drugs are particularly beneficial for patients afflicted with chronic kidney disease (CKD), where long-term treatment adherence and convenience become vital. For instance, in 2023, the US Food and Drug Administration (FDA) approved Jesduvroq (daprodustat) as the first once-a-day oral treatment for anemia associated with CKD in adults who are undergoing dialysis for at least four months. The typical treatment before this was approved by the FDA was injected into the bloodstream. Additionally, Roxadustat is another such oral drug for CKD-associated anemia, which was developed by FibroGen in partnership with AstraZeneca. These innovations help in providing patients with more options for anemia treatment, thereby driving demand and creating growth opportunities for pharmaceutical companies that specialize in anemia drugs.

Boost Your Company's Decisions by Getting a Free Sample Right Away- https://www.marknteladvisors.com/query/request-sample/anemia-drugs-market.html

What are the Key Segments in the Anemia Drugs Market?

The Anemia Drugs is categorized into notable segments, which help in understanding the structure, dynamics, and opportunities within the market. These segments are typically based on:

• By Anemia Type
  • Iron Deficiency Anemia – Market Size & Forecast 2020–2030, USD Million
  • Pernicious Anemia – Market Size & Forecast 2020–2030, USD Million
  • Aplastic Anemia – Market Size & Forecast 2020–2030, USD Million
  • Hemolytic Anemia – Market Size & Forecast 2020–2030, USD Million
  • Sickle Cell Anemia – Market Size & Forecast 2020–2030, USD Million
  • Thalassemia – Market Size & Forecast 2020–2030, USD Million
  • Others – Market Size & Forecast 2020–2030, USD Million
• By Route of Administration
  • Oral – Market Size & Forecast 2020–2030, USD Million
  • Injectable – Market Size & Forecast 2020–2030, USD Million
• By Distribution Channel
  • Hospital Pharmacies – Market Size & Forecast 2020–2030, USD Million
  • Retail Pharmacies – Market Size & Forecast 2020–2030, USD Million
  • Online Pharmacies – Market Size & Forecast 2020–2030, USD Million
  • Others – Market Size & Forecast 2020–2030, USD Million

View Full Report (All Data, In One Place): https://www.marknteladvisors.com/research-library/anemia-drugs-market.html (Explore in-depth analyses, technological trends, and investment patterns.)

How does geographical analysis highlight in the Anemia Drugs market?

By Region

·       North America

·       South America

·       Europe

·       The Middle East & Africa

·       Asia-Pacific

Who are the Key Players in Anemia Drugs Market?

·       Amgen Inc.

·       Pfizer Inc.

·       GlaxoSmithKline plc

·       Biocon Ltd.

·       Bluebird bio, Inc.

·       Eli Lilly and Company

·       Johnson & Johnson Services, Inc.

·       Bayer AG

·       GlycoMimetics, Inc.

·       Regen Biopharma Inc.

·       Acceleron Pharma

·       F. Hoffmann-La Roche Ltd.

·       Novartis AG

·       Zydus Lifesciences Ltd.

Talk to Our Industry Analyst: https://www.marknteladvisors.com/query/talk-to-our-consultant/anemia-drugs-market.html (Get personalized insights into company strategies and regional market dynamics.)

Anemia Drugs Market News

September 2024: Pfizer Inc. announced that it voluntarily withdrew all lots of OXBRYTA ® (voxelotor), which is used for the treatment of sickle cell disease (SCD), in all the markets where it was approved. It also discontinued all active voxelotor clinical trials as well as the expanded access programs worldwide. This decision by Pfizer Inc. was taken because they had researched the clinical data, which indicated that the overall benefit of OXBRYTA no longer outweighed the risk in the approved sickle cell patient population.

April 2024: Zydus Lifesciences announced that China’s National Medical Products Administration of China (NMPA) accepted the New Drug Application (NDA) for Desidustat tablets. The Phase III trial of the drug in China showed positive results. 

Key pillars of the research methodology include:

Scope & Research Design – Clearly defined objectives with tailored qualitative and quantitative methods, backed by precise timelines and budgets.

Sample Selection & Data Collection – Representative samples achieved through proven techniques like random and stratified sampling, supported by reliable tools such as surveys, interviews, and observations.

Data Analysis & Validation – Rigorous cleaning, advanced statistical modeling, and thematic analysis ensure accuracy, reliability, and minimal bias.

Forecasting & Finalization – Predictive modeling and time-series analysis anticipate future market behaviors, presented through insightful reports with charts, graphs, and strategic recommendations.

"Our methodology reflects the trust businesses place in us. By combining innovation with precision, we deliver not just numbers, but clarity and direction for decision-makers worldwide," said a spokesperson for MarkNtel Advisors.

Why This MarkNtel Advisors Research Report:

• In-depth Market Analysis: Understand trends and dynamics shaping growth.
• Segmented Insights: Target specific segments for focused strategies.
• Geographical Performance: Assess market opportunities by geographic area.
• Emerging Technologies: Discover advancements like AI integration.
• Risk Identification: Pinpoint challenges to inform strategic planning.
• Future Forecasts: Prepare for market changes with actionable projections.

Gain exclusive access to our comprehensive insights on the Future of Anemia Drugs Market. With tailored licensing options, including Mini Report Pack, Excel Data Pack, Single User, Multiuser, and Enterprise Packs, our research empowers organizations to navigate dynamic market trends effectively.

Select a License That Matches Your Business Requirements with Instant Offer - https://www.marknteladvisors.com/pricing/anemia-drugs-market.html

About Us:

MarkNtel Advisors is a globally recognized market research and consulting firm delivering intelligence across the healthcare industry, spanning pharmaceuticals, medical devices, healthcare IT, and biotechnology. Our analysts combine domain expertise with innovation tracking to help healthcare organizations improve efficiency and patient outcomes. Through Consulting Services, we assist clients in interpreting insights, designing go-to-market strategies, and adapting to regulatory changes, fostering sustainable growth in the evolving global healthcare ecosystem.

Reach Us:

MarkNtel Advisors

Office No.109, H-159, Sector 63, Noida, Uttar Pradesh-201301, India

Contact No: +91 8719999009

Email: sales@marknteladvisors.com

Visit our Website: https://www.marknteladvisors.com

Trending Blogs - https://www.marknteladvisors.com/blogs